EU and FDA GMP Regulations: Overview and Comparison
|
|
- Cory Haynes
- 6 years ago
- Views:
Transcription
1 THE QUALITY ASSURANCE JOURNAL, VOL. 2, (1997) EU and FDA GMP Regulations: Overview and Comparison The increasing emphasis on global supply of drug products, as well as starting materials and investigational materials, along with international agreements between regulatory authorities, requires Quality Professionals to be versed in the GMP requirements of other nations. In particular, knowledge of both EU and US GMPs is becoming a necessary aspect of doing business in today s market. The foundations of the EU and US GMP systems, an overview comparison of drug product GMP regulations and a summary of the status of regulations is presented. INTRODUCTION John G. Grazal Specialist Microbiologist (American Academy of Microbiology), Senior Manager, International Compliance Group, Zeneca Pharmaceuticals, Zeneca Inc., Wilmington, Delaware, USA David S. Earl Qualified Person (as defined by Article 23 of EC Directive 75/319), Quality Assurance Manager, Quality Assurance Dept., Zeneca Pharmaceuticals, Macclesfield, UK In 1989, the European Council delegated to the Commission the task of adopting measures to strengthen the control of manufacture of medicinal products by means of a directive and guidelines on good manufacturing practice. The Commission used the Community Guide to Good Manufacturing Practice, prepared by a working party of Community pharmaceutical inspectors, as the basis for the Directives 91/356 and 91/412/EEC which established the principles and guidelines for good manufacturing practice for medicinal products for human and veterinary use, respectively. There is no difference in GMPs between the two directives and subsequent reference will be to 91/356/EEC. The GMP principles are interpreted with reference to detailed guidelines published by the European Commission in the Guide to Good Manufacturing Practice for Medicinal Products (GMP Guide), contained within Volume IV of the Rules Governing Medicinal Products in the European Community (1). The US first promulgated GMP regulations in These were updated in 1971, and a major revision was written in 1978 which, notwithstanding several clarifying revisions, remains in effect today. The GMP requirements for human drugs are contained in regulations 21 Code of Federal Regulations (CFR) Parts 210 and 211 (2). These laws are binding regulations which are to be considered minimum standards below which products are deemed adulterated. The regulations apply to both human and veterinary drug products. FDA enforces current good manufacturing practices (CGMP) based on the CGMP provision in the Food Drug and Cosmetic (FD & C) Act. This provision states that a drug is deemed adulterated if the methods used in, or the facilities used for drug product manufacture, processing, packing, or holding do not conform to or are not operated or administered in conformity with CGMP. If a practice is not specified in the regulations, FDA must prove that the practice is CGMP. EC GMP DIRECTIVES AND US REGULATIONS The EC GMP Directives contain the principles and guidelines for medicinal drug manufacture. These laws are made up of 16 articles which lay down the legal framework that member states and manufacturers must comply with. EC Directive 91/356/EEC contains three chapters. Chapter 1 (Articles 1 5) General Provisions, requires repeat CCC/ /97/ $ John Wiley & Sons, Ltd.
2 56 John G. Grazal and David S. Earl Table 1. EU Principles and Guidelines of GMP Quality management Personnel Premises and equipment Documentation Production Quality control Work contracted out Complaints and product recall Self inspection inspections by member states, establishes the GMP Guide as the means of interpretation of the principles and guidelines, requires importers of product from third countries to ensure equivalent standards of manufacture to those in EC Rules Volume IV, and states that manufacturers shall ensure compliance with the marketing authorization. Chapter 2 (Articles 6 14) promulgates the principles and guidelines of GMP for medicinal products for human use (Table 1). Chapter 3 (Articles 15 and 16) The Final Provisions, directs member states to implement the directives into national law. It is the principles outlined in EC Directive 91/356 which provide the legal basis for GMP in the EU. EC member states were expected to bring into force the laws, regulations and necessary administrative provisions to comply with the Directive no later than 1 January The UK Medicines Act was updated by Statutory Instrument 2846 on 11 December Other member states followed later and made compliance with the principles of GMP statutory. The difference in timings can be attributed to the definition of an EC Directive which is a mechanism for providing a framework for national legislation by setting out broad principles and criteria for regulating a particular subject. Directives are binding but leave the method of achieving the outcome, within specified time limits, to the individual states. The US GMP regulations are contained in the CFR Title 21, Food and Drugs, Parts 210 and 211. Part 210 provides the framework for the regulations along with some definitions. Part 211 states the requirements (Table 2). These GMP regulations are Federal Law. The CFR contains the rules published in the Federal Register by the Executive departments and agencies of the US Federal Government. The document is divided into 50 titles representing broad areas subject to Federal regulation. Title 21, covering food and drugs, is updated annually in April. By law, all proposed regulations must be published in the Federal Register to allow a minimum of 30 days for public review and comment before becoming final. The publication of a Table 2. US CMP Regulations for Finished Pharmaceuticals General provisions Organization and personnel Buildings and facilities Equipment Control of components and drug product containers and closures Production and process controls Packaging and labelling control Holding and distribution Laboratory controls Records and reports Returned and salvaged drug products final food or drug regulation in the Federal Register is accompanied by a summary of each type of comment submitted on the proposal along with the FDA Commissioner s conclusions. The Commissioner s rationale (preamble) for accepting or rejecting a comment represents FDA s position on specific GMP requirements and serves as an invaluable reference when interpreting Title 21 Parts 210 and 211. Failure to comply with any of the GMP regulations in 21 CFR renders the drug adulterated under the FD & C Act. With that, the drug and the individuals responsible for the failure to comply shall be subject to regulatory action. EC AND US GMP GUIDELINES The stated purpose of guideline information for both the EU and the US is very similar. Both represent current acceptable practice by providing detailed guidance which interprets and expands on the principles or regulations. Guideline requirements are used by the regulatory authorities in both the EU and the US when assessing applications (Manufacturing and Marketing Authorizations, New Drug Applications (NDAs), Abbreviated new Drug Applications (ANDAs)) as well as a basis for inspections of manufacturers. The regulatory authorities allow implementation of alternate methods to those stated in guideline documents providing equivalent assurance is established. The risk in adopting alternate methods lies in justifying and documenting equivalence to the authorities. In short, guidelines list principles and practices which are acceptable; they do not list the principles and practices that must, in all instances, be used to comply with law. Neither the EC Guide or the FDA guidance documents carry the legal sanction of the principles or regulations. Volume IV of The Rules and Guidance Governing Medicinal Products In The
3 EU and FDA GMP Regulations 57 Table 3. EU GMP Guide Chapters and Annexes Chapters Annexes 1. Quality management 1. Sterile medicinal products 2. Personnel 2. Biological medicinal products for human use 3. Premises and equipment 3. Radiopharmaceuticals 4. Documentation 4. Veterinary medicinal products other than immunologicals 5. Production 5. Immunological veterinary medicinal products 6. Quality Control 6. Medicinal gasses 7. Contract manufacture and analysis 7. Herbal medicinal products 8. Complaints/product recall 8. Sampling of starting and packaging materials 9. Self-inspection 9. Liquids, creams and ointments 10. Pressurized metered dose aerosol preparations for inhalation 11. Computerized systems 12. Ionizing radiation in the manufacture of medicinal products 13. Investigational medicinal products 14. Products derived from human blood or human plasma Table 4. Examples of FDA Guidance Documents Guidelines Inspection guides Validation Pharmaceutical QC laboratories Bacterial endotoxin testing using LAL Lyophilization of parenterals Stability High purity water systems Aseptic processing Validation of cleaning processes Clinical Supplies Microbiological QC laboratories Repackaging Bulk pharmaceutical chemicals European Community titled Good Manufacturing Practice for Medicinal Products contains the nine Chapters and 13 Annexes which make up the GMP Guide. The chapter titles and the annexes are listed in Table 3. Examples of FDA GMP guidance documents are listed in Table 4. Additional sources of current GMPs (CGMPs) can be found in international guidelines such as the World Health Organization (WHO) GMP Guidelines, International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) Guidelines, International Organization for Standards (ISO) standards, and Pharmaceutical Inspection Cooperation Scheme (PICS) Guidelines. Common practices within the industry, license reviews, and crisis management control are also sources of CGMPs. REGULATION OVERVIEW AND COMPARISON The subject areas of both the US and EU GMP regulations are very similar. The US regulations are lengthier and more prescriptive by incorporating detail which, in the EU scheme, is included in the Guide to GMP. An overview comparison keying on the EU GMP Principles and Guidelines is presented. Article 6 of the EU Principles requires an effective quality assurance system involving management s active participation. Article 11 outlines the responsibilities of the quality control department. It is useful to review both Articles together. The terms quality control department (EU), and quality control unit (US) do not discriminate between laboratory control and the responsibilities of the group most often referred to in industry as Quality Assurance (QA). Nevertheless, concepts such as batch record review, ensuring conformity to specifications, adequate laboratory facilities, and a reserve sample programme are common to both sets of regulations. EU regulations require a reserve (retained) sample of starting materials be held for at least 2 years after the release of the product. The US require a reserve sample of the active ingredient to be retained for 1 year after the expiration date of the last lot of drug product containing the active ingredient. The US regulations emphasize written procedures, in many cases detailing minimum requirements. The EU regulations leave the detail of written procedures to the GMP Guide.
4 58 John G. Grazal and David S. Earl Both sets of regulations allow the use of outside laboratories to carry out the quality control functions necessary for examination and testing of materials. The thrust of the regulations is that adequate laboratory facilities be available to the quality function, not that the facilities be owned and operated by the drug product manufacturer. However, the drug product manufacturer is ultimately responsible for ensuring the contract laboratory operates to GMP. In the EU legal action can be taken against the Heads of Production and Quality Control and the Qualified Persons... The regulations in both the EU and the US assign the responsibility for quality manufacturing practices to senior management. In the US, products are deemed adulterated based on either laboratory examination of drug products or on the basis of objectionable conditions observed during manufacturing or holding of the drug products. The latter means of determining product adulteration results from an FDA conclusion that the product(s) were not manufactured in accordance with CGMP. When products have been found to be adulterated, FDA has both administrative and legal options it can exercise. Administrative actions include issuing Warning Letters and withholding approval of applications. The legal actions in the US include product seizure, debarment of individuals from working in the pharmaceutical industry, court injunctions and prosecution. Where product is manufactured outside the US and been found to be adulterated, FDA has taken administrative actions and in some cases barred import of the drug products into the US. In the EU, besides the powers European inspectors have to seize and detain medicinal products from the manufacturing facility, legal action can be taken against the persons named on the Manufacturers License. These are the Heads of Production and Quality Control and the Qualified Persons (QP). Article 7 of the EU Principles discusses personnel requirements. Organizational charts and job descriptions are required. There are no similar requirements for these documents in the US regulations. Education, experience, and training as the foundation for qualified personnel is integral to both sets of regulations, although the detail in the EU is again covered in the Guide. There is a statutory requirement for initial and ongoing training, including GMP training, in both sets of regulations. Health, hygiene, and clothing for personnel is also addressed in the regulations. Uniquely, CFR Part addresses the use of consultants requiring them to be qualified and mandating the drug product manufacturer to maintain records containing the name, address, qualifications and the type of service performed by these individuals. Article 8 addresses premises and equipment. Chapter 3 of the Guide provides the detail. The CFR Part 211 Subparts C and D cover facilities and equipment in similar detail to the Principles and Guide. The design, construction and operation features of buildings and equipment must be such as to minimize the potential for contamination and quality problems. 211 CFR Subpart C goes into a fair amount of detail on requirements for separate or defined areas for various operations including aseptic processing. Both sets of regulations require buildings and equipment to be maintained. Equipment surfaces that come into contact with product must not be reactive, additive or absorptive (2). Maintenance and cleaning activities are detailed in the CFR while similar requirements are in the EU GMP Guide. Premises and equipment critical to product quality must be subject to appropriate qualification according to Article 8, Item 3. While the wording is less clear, FDA point to 21 CFR Part a, in particular the requirement that equipment be checked according to a written program designed to assure proper performance (2) as the regulation requiring equipment qualification or validation. Separate facilities for penicillin production are addressed in the US regulations and the EU GMP Guide. CFR on sterile filtration covers many of the same details outlined in Annex 1 of the GMP Guide. This section of the CFR should be read in conjunction with the FDA Guideline On Sterile Drug Products Produced By Aseptic Processing 1987, where specific good practices relating to sterile filtration are detailed. Article 9 on documentation coupled with Chapter 4 of the GMP Guide provides a comprehensive and detailed set of requirements related to documentation. CFR 211 Subpart J, Records and Reports, details the US requirements. The similarity in content and detail between the documentation requirements should provide firms on both sides of the Atlantic with adequate instruction to meet FDA s inspectional emphasis on documentation.
5 EU and FDA GMP Regulations 59 Based on the number of FDA 483 observations related to documentation deficiencies, this does not appear to be the case. Both EU and US regulations require that documents be available for inspection purposes. The use of electronic storage for documents is recognized provided the system has been validated. Article 10 on production covers process validation and revalidation requirements. CFR Part 211 is scant in the area of process validation. This appears at odds with both the US industry and FDA s emphasis on validation. Clearly, process validation CGMPs have evolved without benefit of detailed regulation in this area. It must be remembered that the last major revision of 21 CFR was in Validation GMPs have progressed significantly since that time. A draft revision to 21CFR Parts 210 and 211, published by FDA in 1996 includes more specific validation requirements which have drawn negative comment from industry. Whilst time limits are discussed in Part and apply to all drug products, the European approach to this process control is reserved for the GMP Guide Sterile Products Annex. Article 11 was discussed in the context of QA/QC. Article 12 is devoted to work contracted out. The requirement for a written contract defining responsibilities between each party is unique to the European regulations. The EU provisions around inspections and subcontracting are GMP practices in the US. However, these requirements along with QP responsibilities (not recognized in the US) are not part of the GMP regulations. It is noteworthy that in the US, the quality control unit of a contract facility is required to approve or reject drug products produced by the contractor but the final release to market is to be performed by the owner of the drug product. In the EU, this distinction is not made provided the release is done by a QP. All holders of Manufacturers Licenses within the EU are required to have the services of a QP as defined in EC Directive 75/319. No batch of medicinal product may be released to the market within the EU unless a nominated QP has certified that it has been manufactured and checked in compliance with the laws in force. Article 13 on complaints and product recall outlines the requirements in these areas. Written procedures, investigations, and alerting the regulatory authorities are common to both systems. Recalls are voluntary in both the US and the EU. Both sets of regulations refer the reader to further guidance/regulation on the conduct of recalls. Firms have been cited on FDA Form 483 for not having an internal audit plan... Article 14 on Self Inspections does not have an equivalent in the US GMP regulations. While it is certainly CGMP to perform internal auditing, and the FDA expectation is that firms do so, there is no legal requirement in the US regulations. Firms have been cited on FDA Form 483 observations for not having an internal audit plan or for failing to carry out scheduled audits. STATUS OF GMP REGULATIONS IN THE EU AND US The draft revision of CFR Parts 210 and 211 mentioned above was published in a 6 May 1996 submission to the Federal Register. The Agency has stated that the reason for the proposed revisions to the regulations is to clarify requirements in certain areas of GMP that have been the subject of recent enforcement actions. Industry has commented that the proposed regulations impose substantial new requirements that do not contribute to the quality or safety of drug products. FDA is reviewing the industry comments and is expected to issue a final revision in Currently there are no statutory GMP regulations for active pharmaceutical ingredients (APIs) in either the EU or the US. While the FDA has an active inspection programme for APIs and uses CFR Parts 210 and 211, these regulations are used as guidelines only. APIs manufactured for use in drug products for the US market are required to conform to GMP since the Food, Drug and Cosmetic Act makes no distinction between drug substances and drug products, but there are no formal regulations. A similar situation exists in the EU, although there is no formal inspection programme for APIs. FDA released a draft guidance Manufacture, Processing, or Holding of Active Pharmaceutical Ingredients in October FDA is reviewing industry comment to this proposal and the final revision is expected in A legal GMP framework (regulations and guidelines) has been proposed in the EU for starting materials. This would establish both routine and
6 60 John G. Grazal and David S. Earl for cause inspections for selected starting materials including all active agents and certain excipients. These listed starting materials would be required to be manufactured in accordance with the regulations and guidelines. Inspections of third country starting material manufacturers is also called for. Investigational materials or clinical supplies must conform with the drug product CFRs for manufacture and/or distribution in the US. In the EU, these materials are not currently subject to statutory requirements. While the EU principles and guidelines, along with the detailed guidelines are relevant to the manufacture of investigational materials, it is Annex 13 in the GMP Guide which provides the framework for common standards in the area of investigational materials. CONCLUSIONS Pharmaceutical manufacture and regulation is clearly an international business. With the increasing emphasis on harmonization efforts and standard setting along with mutual recognition agreements, knowledge of foreign regulations is a necessity for both understanding the future direction of these efforts as well as for international supply of drug products. This paper presented some background information and an overview of drug GMP regulations and guidelines in the EU and the US. The laws and principles relating to GMP are fundamentally similar between the EU and the US. It is the detailed guidelines and their application where the differences arise, and even here there is much that is similar. As with any overview, there is much detail which is not covered. The intent of this article is to introduce the reader to the regulations and provide a starting point for further investigations. REFERENCES 1. Commission of the European Communities. The Rules Governing Medicinal Products in the EC. Vol. IV. Good Manufacturing Practice for Medicinal Products. Luxembourg: Office for Official Publications of the EC, ISBN X. 2. Food and Drug Administration, Department of Health and Human Services. 21CFR 210, 211. Washington: Office of the Federal Register National Archives and Records Administration, 1997.
GMP GUIDELINES. GMP Guides from Industry Organisations. FDA cgmp WHO GMP. cgmp Guide Drugs 21 CFR 210 GAMP. ISPE Technical Guides
FDA cgmp cgmp Guide Drugs 21 CFR 210 cgmp Guide Drugs 21 CFR 211 cgmp Guide Medical Device 21 CFR 808, 812, 820 cgmp Guide Biologics 21 CFR 600, 606, 610 Guideline List Human Drugs Guideline List Biologics
More informationSubpart B Organization and Personnel, 21 CFR Responsibilities of the quality control unit.
FDA inspections continue to focus on CGMP violations related to basic GMP controls. A survey of Warning Letters issued in 2013 on CMC (Chemistry / Manufacturing / Controls) violations reveals an emphasis
More informationA.1 Contents file 4 to 5 A.1 (1)
Contents file 4 to 5 Contents file 4 to 5 A Information Contents file 4 to 5 A.2 Index file 4 to 5 A.3 List of Abbreviations A.4 Glossary A.5 Adress-Register A.6 References B Japanese Regulations B.1 MHW
More informationEuropean Union (EU) Regulatory Trends in GMP. Clive Brading Tianjin, China September 23, 2009
European Union (EU) Regulatory Trends in GMP Clive Brading Tianjin, China September 23, 2009 -2- Presentation Topics EU Background Inspections outside the EU EMEA Inspection Outcomes Dedicated Facilities
More informationEUROPEAN INDUSTRIAL PHARMACISTS GROUP. Guidance on CPD for QUALIFIED PERSONS
EUROPEAN INDUSTRIAL PHARMACISTS GROUP Guidance on CPD for QUALIFIED PERSONS EIPG Guidance on CPD for QP Continuing Professional Development for Qualified Persons, Technical Directors and other Responsible
More informationGood manufacturing practices
The rules governing medicinal products in the European Union Volume 4 Good manufacturing practices Medicinal products for human and veterinary use 1998 Edition EUROPEAN COMMISSION Directorate General III
More informationJournal of Chemical and Pharmaceutical Research
Available online www.jocpr.com Journal of Chemical and Pharmaceutical Research ISSN No: 0975-7384 CODEN(USA): JCPRC5 J. Chem. Pharm. Res., 2011, 3(6):88-98 Conduct of Inspections for Pharmaceutical Manufactures
More informationWhile the recognition
Designing the Perfect Change Control System Change control systems today are expected to be designed in a way that provides a system to not only document and approve changes, but also to anticipate change
More informationWebinar Expert Module 3: GMP Inspections Dupont
Webinar Expert Module 3: GMP Inspections Dupont 26 January & 9 February 2018 GOP-Innovations your Partner for Practical Training and e-learning Milenko Pavičić Pharmaceutical microbiologist, trainer, coach
More informationCGMP Requirements for Investigational Products
PREP #6 CGMP Requirements for Investigational Products Ji-Eun Kim, RPh, PhD Research Pharmacist Regulatory Affairs Office of Research Compliance December 6, 2016 1 CME Disclosure Statement Northwell Health
More informationEUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY. EudraLex. Volume 4
EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY Ref. Ares(2015)4234460-12/10/2015 Medicinal products quality, safety and efficacy Brussels, 12 October 2015 EudraLex Volume 4 EU Guidelines
More informationQuality Agreements with CMO s. Presented at ASQ Orange Empire Meeting May 13, 2014 By Luke Foo Sr. Director QA/QC Spectrum Pharmaceuticals
Quality Agreements with CMO s Presented at ASQ Orange Empire Meeting May 13, 2014 By Luke Foo Sr. Director QA/QC Spectrum Pharmaceuticals FDA Guidance Contract Manufacturing Arrangements for Drugs: Quality
More informationOverview of Regulatory Requirements for API and Formulations
Overview of Regulatory Requirements for API and Formulations Sangeeta Sardesai 4-Dec-2010 Definition - Regulatory Requirement The restrictions, licenses, and laws applicable to a product or business, imposed
More informationSan Jose, California, USA
Glisland, Inc. San Jose, California, USA http://www.glisland.com Welcome to the Drug GMP World Current Good Manufacturing Practice cgmp ICH Q10 Pharmaceutical Quality System PQS GMP QSR Quality System
More informationInspection Trends. American Society for Quality Richmond, VA Section March 8, 2016
Inspection Trends American Society for Quality Richmond, VA Section March 8, 2016 Brooke K. Higgins, Senior Policy Advisor CDER / Office of Compliance Office of Manufacturing Quality Division of Drug Quality
More informationCGMP for Phase 1 INDs
CGMP for Phase 1 INDs Laurie P. Norwood Deputy Director Division of Manufacturing and Product Quality Office of Compliance and Biologics Quality Center for Biologics Evaluation and Research 1 Overview
More informationQuality Assurance in Pharmaceutical and Biotech Industries as Per Regulatory Guidelines
Human Journals Review Article January 2017 Vol.:8, Issue:2 All rights are reserved by Chagi Venkatesh et al. Quality Assurance in Pharmaceutical Biotech Industries as Per Regulatory Guidelines Keywords:
More informationRegulatory Requirements & Recent Changes, including expectations for APIs & IMPs
Regulatory Requirements & Recent Changes, including expectations for APIs & IMPs Neil Raw - GMP Inspector Richard Andrews - Operations Manager 11 th November 2008 Programme: Regulatory Requirements Neil
More informationWorking Party on Control of Medicines and Inspections. Final Version of Annex 16 to the EU Guide to Good Manufacturing Practice
Version 8 (final) EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Single market, regulatory environment, industries under vertical legislation Pharmaceuticals and cosmetics Brussels, July 2001 Working
More informationCompliance Trends Paula Katz
Compliance Trends Paula Katz Director, Manufacturing Quality Guidance and Policy Staff Office of Manufacturing Quality Office of Compliance Center for Drug Evaluation and Research India Pharmaceutical
More informationPhase Appropriate GMPs for IMPs. Presented by: Karen S. Ginsbury For: IFF, October 31, Nov 02, 2017
Phase Appropriate GMPs for IMPs Presented by: Karen S. Ginsbury For: IFF, October 31, Nov 02, 2017 1 Lets start with References https://mhrainspectorate.blog.gov.uk/2016/0 5/20/manufacture-of-investigationalmedicinal-products-frequently-askedquestions/
More informationProduction of radiopharmaceuticals for clinical and research uses
Production of radiopharmaceuticals for clinical and research uses The European perspective Philip Elsinga UMC Groningen The Netherlands The Rules European players in (radio ) pharmaceutical legislation
More informationDrug Quality Assurance: Systems at ChemCon Author: Dr. Peter Gockel
Drug Quality Assurance: Systems at ChemCon Author: Dr. Peter Gockel On February 13th, 2006, the FOOD AND DRUG ADMINISTRATION (FDA) implemented a revision to the Compliance Program Guidance Manual for active
More informationHow to Select a Microbiology Contract Testing Laboratory? Tony Cundell, Ph. D. Microbiological Consulting, LLC Scarsdale, New York
How to Select a Microbiology Contract Testing Laboratory? Tony Cundell, Ph. D. Microbiological Consulting, LLC Scarsdale, New York June 13, 2017 IVT Microbiology Week 1 Presentation Overview Rationale
More informationIntroduction and Case Sharing of FDA CGMP Inspections
Presentation title Date Introduction and Case Sharing of FDA CGMP Inspections Second Russian GMP Conference 2017 Andrew Chang, Ph.D Vice President, Quality and Regulatory Compliance Novo Nordisk A/S Presentation
More informationLibrary Guide: Active Pharmaceutical
Library Guide: Active Pharmaceutical Ingredients (API) Table of Contents Overview...3 Sample Curriculum...5 Course Descriptions: A Step-by-Step Approach to Process Validation (PHDV79)...7 A Tour of the
More informationINTRODUCTION TO THE QUALITY SYSTEMS APPROACH TO CGMP COMPLIANCE
001_005.qxd 24/2/06 19:46 Page 1 CHAPTER 1 INTRODUCTION TO THE QUALITY SYSTEMS APPROACH TO CGMP COMPLIANCE 1.1 OVERVIEW OF QUALITY SYSTEMS The Food and Drug Administration (FDA) mandates that a drug firm,
More informationAnnual product quality review: Guidance for industry by regulatory perspective
International Journal of Medicine Research ISSN: 2455-7404; Impact Factor: RJIF 5.42 www.medicinesjournal.com Volume 2; Issue 4; July 2017; Page No. 01-10 Annual product quality review: Guidance for industry
More informationPharmacy Compounding of Human Drug Products Under Section 503A of the Federal Food, Drug, and Cosmetic Act
Pharmacy Compounding of Human Drug Products Under Section 503A of the Federal Food, Drug, and Cosmetic Act Guidance U.S. Department of Health and Human Services Food and Drug Administration Center for
More informationGood Manufacturing Practice ( GMP ) Compliance: GMPs EXPLAINED
Good Manufacturing Practice ( GMP ) Compliance: GMPs EXPLAINED Presented by Raymond A. Bonner Nathan C. Sheers SIDLEY AUSTIN BROWN & WOOD, LLP Washington, D.C. (202) 736-8000 To The Fourth Annual Pharmaceutical
More informationGood Manufacturing Practices Purpose and Principles of GMP. Tony Gould
Good Manufacturing Practices Purpose and Principles of GMP Tony Gould Why GMP? Provides a high level assurance that medicines are manufactured in a way that ensures their safety, efficacy and quality Medicines
More informationPHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME. PI July 2018
PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME PI 045-1 1 July 2018 GUIDELINES ON THE FORMALISED RISK ASSESSMENT FOR ASCERTAINING THE APPROPRIATE GOOD MANUFACTURING
More informationSupply Chain Supplier Quality Management. Nicholas Violand, Investigator/Drug Specialist US FDA, New Jersey District
Supply Chain Supplier Quality Management Nicholas Violand, Investigator/Drug Specialist US FDA, New Jersey District 1 Overview Product Life Cycle Maintaining Quality in Supply Chain FDA and ICH Guidances
More informationPharmaceutical Reference Standards: Overview and Role in Global Harmonization
Matthew Borer, Ph.D., Advisor Pharmaceutical Reference Standards: Overview and Role in Global Harmonization 3rd DIA China Annual Meeting Beijing, China, 16-18 May, 2011 What is a Pharmaceutical Reference
More informationFDA Quality Metrics, Data Integrity and Application of Statistics Throughout Process Validation in a Global Economy
CBI Statistics in Validation FDA Quality Metrics, Data Integrity and Application of Statistics Throughout Process Validation in a Global Economy Jerry Lanese Ph.D. The Lanese Group, Inc. 2017 The Lanese
More informationGood practices in quality control in pharmaceutical industry - Overview of regulatory guidelines
Review Article Good practices in quality control in pharmaceutical industry - Overview of regulatory guidelines Chagi Venkatesh*, S. B. Puranik ABSTRACT Good practices in quality control (QC) department
More informationDeficiencies found in Inspections and QP Responsibilities
Deficiencies found in Inspections and QP Responsibilities Ciara Turley, HPRA Inspector QP Forum, Trinity College, Dublin 25 th April 2017 Dublin Key QP Responsibilities Chapter 1, 1.4 (xv) Medicinal products
More informationValidation Needs for Sterilization by Aseptic Filtration
Validation Needs for Sterilization by Aseptic Filtration DCVMN Workshop, Hyderabad, 4-8 April 2016 Ramesh Raju Associate Director - Provantage Validation Services Overview Key Regulatory and Industry guidelines
More informationJournal home page: RESEARCH ARTICLE
Journal home page: http://www.journalijiar.com INTERNATIONAL JOURNAL OF INNOVATIVE AND APPLIED RESEARCH RESEARCH ARTICLE QUALITY AUDIT AND GMP INSPECTION OF PHARMACEUTICAL INDUSTRY WITH REFERENCE TO USFDA;
More informationRegulatory Aspects of Cleaning and Cleaning Validation. Larry Greenstein Quality Operations, Quality Unit, Bio-Technology General, Ltd.
Regulatory Aspects of Cleaning and Cleaning Validation Larry Greenstein Quality Operations, Quality Unit, Bio-Technology General, Ltd. 28 June 2017 Why clean? Pharmaceutical production equipment is cleaned
More informationGuidance for Industry Quality Systems Approach to Pharmaceutical Current Good Manufacturing Practice Regulations
Guidance for Industry Quality Systems Approach to Pharmaceutical Current Good Manufacturing Practice Regulations DRAFT GUIDANCE This draft guidance document is being distributed for comment purposes only.
More informationThe ABCs and Challenges of GMP The American Experience
The ABCs and Challenges of GMP The American Experience The Canadian Association of Nuclear Medicine Toronto, Ontario April 22, 2017 Reiko Oyama, R.Ph., B.C.N.P. Washington University School of Medicine
More informationAnnex A2. Guidance on Process Validation Scheme for Aseptically Processed Products
Annex A2 Guidance on Process Validation Scheme for Aseptically Processed Products 1 Table of content 1 PURPOSE... 3 2 SCOPE... 3 3 GENERAL INFORMATION... 3 4 INFORMATION NEEDED FOR ASEPTIC PROCESSES VALIDATION...
More informationUSP Chapter 823 USP 32 (old) vs. USP 35 (new)
USP Chapter 823 USP 32 (old) vs. USP 35 (new) Sally W. Schwarz, MS, BCNP Research Associate Professor of Radiology Washington University School of Medicine St. Louis, MO Why USP Chapter ? FDA has
More informationSupersedes Division Name Revision No. 0 Export Division Page No. 1 of 9
Page No. 1 of 9 Control Status 1.0 Purpose To lay down a procedure for conducting GMP inspection and report writing for issue of Written Confirmation for for medicinal products for human. 2.0 Scope This
More informationJeff Yuen and Associates, Inc. PO Box 6026 Orange, CA Zenaida Power Regulatory Expertise:
Regulatory Expertise: Pharmaceuticals: Sterile-Liquids, Non-Sterile Liquids, Solid Oral Dosage Form, Parenterals, Antibiotics, APIs/Bulk Chemicals, Creams & Ointments Medical Devices: Implantable / Active
More informationQualified Persons in the Pharmaceutical Industry. Code of Practice. March 2008
Qualified Persons in the Pharmaceutical Industry Code of Practice March 2008 Updated October 2009 Code of Practice for Qualified Persons 1. INTRODUCTION... 1 2. REGULATORY BASIS FOR THE QUALIFIED PERSON...
More informationTrinity College Dublin QP Forum 2017 Tuesday 25 th April
Trinity College Dublin QP Forum 2017 Tuesday 25 th April HPRA QUESTIONS & ANSWERS 1. What is the approach being taken for audit of contamination control strategies as per chapters 3 & 5? What is the current
More informationGMP On Site Series. GMP Essentials
GMP On Site Series GMP Essentials GMP Basics Objectives 1. State the critical definitions of the pharmaceutical industry. 2. Describe the law as it applies to various critical functions. 3. State the history
More informationGUIDELINES FOR INTRODUCING A LOCALLY MANUFACTURED NEW PHARMACEUTICAL PRODUCT ON THE UGANDA MARKET
GUIDELINES FOR INTRODUCING A LOCALLY MANUFACTURED NEW PHARMACEUTICAL PRODUCT ON THE UGANDA MARKET National Drug Authority Head Office Rumee Towers Plot 19, Lumumba Avenue P. O. Box 23096 Kampala, Uganda
More informationImpact of EU GMPs on Australian GMP. Trevor Schoerie PharmOut
Impact of EU GMPs on Australian GMP Trevor Schoerie PharmOut Part I Basic Requirements for Medicinal Products Current TGA Version, 7 years out of date TGA are actively and publically talking about PE009-0813
More informationEUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. EudraLex. The Rules Governing Medicinal Products in the European Union
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Public Health and Risk Assessment Medicinal Product quality, safety and efficacy Brussels, 16 August 2013 EudraLex The Rules Governing Medicinal
More informationNavigating an FDA GMP and Validation Inspection- Best Practices and Pitfalls
Navigating an FDA GMP and Validation Inspection- Best Practices and Pitfalls Sonali P. Gunawardhana FDA Practice Group Wiley Rein LLP 1776 K Street NW Washington, DC (202) 719-7454 sgunawardhana@wileyrein.com
More informationLEARNING, TRAINING, AND PERFORMANCE
9 Overview Learning, Training, and Performance Training is one of the most important investments a firm can make as it produces products that meet GMP expectations. Training is not done just for the sake
More informationMANUFACTURE OF INVESTIGATIONAL MEDICINAL PRODUCTS
ANNEX 13 MANUFACTURE OF INVESTIGATIONAL MEDICINAL PRODUCTS Introduction Medicinal products intended for research and development trials are not at present subject either to marketing or manufacturing Community
More informationPROCESS VALIDATION ROCHAPON WACHAROTAYANKUN, PH.D.
Basic GMP Requirement PROCESS VALIDATION ROCHAPON WACHAROTAYANKUN, PH.D. Topic Process validation What and Why? Principle of process validation Manufacturing process validation Aseptic process validation
More informationThe APIC Audit Programme Version 5, July 2017
The APIC Audit Programme Version 5, July 2017 Table of contents 1 General 2. APIC Audit Programme 3 The Auditors 3.1 Educational Background and Experience 3.2 Auditor Training Courses for Certification
More informationChange Control Overview
Change Control Overview Kelly Thomas Atlantic Technical and Validation Services Copyright 2014 by Atlantic Technical and Validation Services, LLC. 1 Session Outline Discuss Regulations Governing Change
More informationApril 12, 2010 WARNING LETTER (10-ATL-12)
Hospira, Inc. Department of Health and Human Services Public Health Service Food and Drug Administration Atlanta District Office 60 8th Street, N.E. Atlanta, Georgia 30309 April 12, 2010 VIA FEDERAL EXPRESS
More informationProcess development and basic GMP
Process development and basic GMP Aulton Chapter 45, handouts Specification, stability, inprocess controls and validation Product development Process development Critical Product Qualities issues Critical
More informationDarshit S. Patel, IJPSR, 2012; Vol. 3(12): ISSN: FDA WARNING LETTER ANALYSIS: A TOOL FOR GMP COMPLIANCE. Darshit S.
IJPSR (2012), Vol. 3, Issue 12 (Review Article) Received on 20 August, 2012; received in revised form 28 September, 2012; accepted 20 November, 2012 FDA WARNING LETTER ANALYSIS: A TOOL FOR GMP COMPLIANCE
More informationAnnex 14 WHO guidelines for drafting a site master file 136
World Health Organization WHO Technical Report Series, No.961, 2011 Annex 14 WHO guidelines for drafting a site master file 136 1. Introduction 2. Purpose 3. Scope 4. Content of site master fi le Appendix
More informationPROPOSED NEW SECTIONS FOR WHO GOOD MANUFACTURING PRACTICES (GMP): MAIN PRINCIPLES FOR PHARMACEUTICAL PRODUCTS DRAFT FOR COMMENT
August 2010 RESTRICTED PROPOSED NEW SECTIONS FOR WHO GOOD MANUFACTURING PRACTICES (GMP): MAIN PRINCIPLES FOR PHARMACEUTICAL PRODUCTS DRAFT FOR COMMENT Please address any comments on this draft guideline
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Page 1 of 5 Home Inspections, Compliance, Enforcement, and Criminal Investigations Compliance Actions and Activities Warning Letters 2014 Inspections, Compliance, Enforcement, and Criminal Investigations
More informationQuality Assessment & GMP Similarities & Differences
Quality Assessment & GMP Similarities & Differences EMEA, Monday 26 th October 2009 Cormac Dalton Inspector Irish Medicines Board Date 12-Oct-09 Slide 1 Content Overview of commonalities & differences
More informationImpacto de las Nuevas Tendencias Regulatorias en la Producción de Parenterales. Innovacion en Packaging Primario
Impacto de las Nuevas Tendencias Regulatorias en la Producción de Parenterales Innovacion en Packaging Primario 1 Contents Company Highlight What s Changing in Pharma Pharma Trends Harmonisation New Requirements
More informationSynopsis: FDA Process Validation Guidance
Synopsis: FDA Process Validation Guidance This synopsis is a comparison of the draft version 2008 and the final version 2011 of the U.S. FDA Guidance Process Validation: General Principles and Practices.
More informationGuidance for Industry
Guidance for Industry Q8, Q9, and Q10 Questions and Answers U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics
More informationProduct quality review for listed Complementary Medicines
Technical Guidance on the Interpretation of Manufacturing Standards Product quality review for listed Complementary Medicines Technical Working Group (TWG) on Complementary Medicines Issue 9-4/3/2010 About
More informationGMP Inspection Deficiencies Review of Deficiencies Observed in 2013.
GMP Inspection Deficiencies 2013 Review of Deficiencies Observed in 2013. Executive Summary The most frequently encountered defect categories raised over the previous five years have remained relatively
More informationRegulations in Pharmaceutical Laboratories
Regulations in Pharmaceutical Laboratories February 2004 Ludwig Huber Compliance Fellow for Life Sciences and Chemical Analysis Chairperson: Rob Sample Regulations and Quality Standards Developed by Industries
More informationGuidance for Industry and FDA:
1227 25th St., NW Washington, DC 20037-1156 Guidance for Industry and FDA: Application of cgmp Regulations to Combination Products: Frequently Asked Questions PROPOSED GUIDANCE January 15, 2007 This guidance
More informationOverview of FDA Regulations and Guidance Documents related to PET Drug Chemistry. Steve Zigler, Ph.D. Siemens PETNET Solutions
Overview of FDA Regulations and Guidance Documents related to PET Drug Chemistry Steve Zigler, Ph.D. Siemens PETNET Solutions Employee of Siemens-PETNET Solutions I will not discuss investigational agents,
More informationUNICEF s Quality Assurance System for Procurement of Finished Pharmaceutical Products
UNICEF s Quality Assurance System for Procurement of Finished Pharmaceutical Products UNICEF Industry Consultation with Manufacturers and Suppliers of Finished Pharmaceutical Products 29 th 30 th September
More informationResponding to an FDA 483
Responding to an FDA 483 Jim Melancon VP, Associate General Counsel BioScrip, Inc. Marc Stranz, PharmD Healthcare Consultant Disclosure The speakers declare no conflicts of interest or financial interest
More informationFacility and Operational Issues for Cord Blood Banks: FDA Draft Guidance
Facility and Operational Issues for Cord Blood Banks: FDA Draft Guidance Mary Malarkey, Director Office of Compliance and Biologics Quality ISCT 7 th Annual Somatic Cell Therapy Symposium, September 26-28,
More informationDECEMBER 2008 GUIDANCE NOTES ON PRODUCT QUALITY REVIEW
DECEMBER 2008 GUIDANCE NOTES ON PRODUCT QUALITY REVIEW 1.0 INTRODUCTION: The purpose of this guidance is to communicate the expectation with regard to the conduct of Product Quality Review. Product Quality
More informationISPE Annual Meeting 29 October 1 November 2017 San Diego, CA
Ministry of Industry and Trade/ Department of pharmaceutical and medical industry development Moscow September 22, 2017 MEDICINES CIRCULATION SYSTEM IN THE RUSSIAN FEDERATION Ministry of Healthcare Medicines
More informationQUESTIONNAIRE FOR COMPETENT AUTHORITIES TO BE USED FOR ASSESSMENT, REASSESSMENT AND SELF- EVALUATION
PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME PS/W 1/2011 2 Annexes 22 July 2011 QUESTIONNAIRE FOR COMPETENT AUTHORITIES TO BE USED FOR ASSESSMENT, REASSESSMENT AND SELF- EVALUATION PIC/S 2011 Reproduction
More informationSITE MASTER FILE For MHRA
ABC CO., LTD. For MHRA Prepared by Date Approved by Date Verified by Date Document No.: SMF, Version No: 01, Effective Date: 09/05/06 Document No.: SMF Version No.: 01 Effective Date: 09/05/06 Page 2 of
More informationQualified Persons in the Pharmaceutical Industry Study Guide
Qualified Persons in the Pharmaceutical Industry Study Guide Guide to the knowledge and practical experience required by Qualified Persons relating to pharmaceutical manufacturing in the UK February 2013
More informationDrug Good Manufacturing Practices Inspections
Drug Good Manufacturing Practices Inspections New England District Investigations Branch Parenteral Drug Association New England Chapter May 17, 2006 DRUG MANUFACTURING INSPECTIONS Inspections Include:
More informationValidation/Verification of Test Methods An FDA Perspective. Laure H. Kairawicz, Ph.D. Senior Scientist Expert Witness
Validation/Verification of Test Methods An FDA Perspective Laure H. Kairawicz, Ph.D. Senior Scientist Expert Witness FD & C Act Overview Definition of drugs What cgmps are Finished Pharmaceuticals cgmp
More informationGMPs: Distribution Centers
SkillsPlus International Inc. The On-Site Series GMPs: Distribution Centers Learn to apply the GMP regulations as they relate to distribution center operations! FDA Past, Present, and Future and opener
More information21CFR Ventilation, air filtration, air heating and cooling. 21CFR211 Details, Details. 21CFR Equipment Cleaning and Maintenance
21CFR211 Details, Details Kirsten L. Vadheim, Ph.D., RAC 7710 196th Avenue N.E. Redmond WA 98053 Tel: 651.260.6560 Fax: 425.868.4302 klvadheim@hotmail.com 21CFR211.46 Ventilation, air filtration, air heating
More informationRegional GMP Strengthening Workshop for Indian Pharmaceutical Manufacturers and State Regulators
Regional GMP Strengthening Workshop for Indian Pharmaceutical Manufacturers and State Regulators Focused on GMP in production of Active Pharmaceutical Ingredients and Oral Solid Dosage Forms Organized
More informationICH Q8/Q8(R)
Pharmaceutical Quality for the 21 st Century Temple University May 06, 2008 Joseph Famulare, Deputy Director FDA CDER Office of Compliance CDER Office of Compliance and the Critical Path Initiative Since
More informationChallenges of the regulatory body in implementing the legislations for the radiopharmaceuticals: efforts of IAEA
2 nd Conference on Radioisotopes Production and Utilization And 11 th Cyclotron Research Workshop 26-27 March 2015 - Monastir (Tunisia) Challenges of the regulatory body in implementing the legislations
More informationEUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. EudraLex. The Rules Governing Medicinal Products in the European Union
Ref. Ares(2014)968036-28/03/2014 EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Health systems and products Medicinal products quality, safety and efficacy Brussels, 28 March 2014 EudraLex
More informationMaterials Management Traceability, CEPs and managing non-conforming sites
Materials Management Traceability, CEPs and managing non-conforming sites IMB Information Day, 14 th October 2010 Dr Cormac Dalton Inspector 13-Oct-10 Slide 1 Managing Supply Supply Demand Supply chain
More informationRole of Industrial Engineer in Compliance with FDA Regulations
Role of Industrial Engineer in Compliance with FDA Regulations Wanda J. Torres Medical Device Specialist Libia M. Lugo Drug Specialist Simposio de Ingeniería Industrial Polytechnic University, San Juan
More informationHealth Canada Mutual Recognition Agreement (MRA) Programme
Health Canada Mutual Recognition Agreement (MRA) Programme Presentation to Association of Food and Drug Officials (AFDO) Kimby Barton, Health Canada June 9, 2018 Overview Regulatory Operations and Regions
More informationISPE NORDIC COP CLEAN UTILITIES SEPTEMBER TUUSULA FINLAND. Timo Kuosmanen STERIS Finn-Aqua
ISPE NORDIC COP CLEAN UTILITIES SEPTEMBER 7 2016 TUUSULA FINLAND Timo Kuosmanen STERIS Finn-Aqua Timo_Kuosmanen@steris.com AUDIT TRAIL IN CRITICAL UTILITIES MONITORING CURRENT TRENDS CONTENTS BACKGROUND
More informationDJ Cockburn Head of Manufacturing and Quality Compliance European Medicines Agency
Introduction to EU Regulatory system and GMP Inspection system. The Qualified Person. DJ Cockburn Head of Manufacturing and Quality Compliance European Medicines Agency Any views expressed may not necessarily
More informationFDA Draft Guidance for Industry Contract Manufacturing Arrangements for Drugs: Quality Agreements (May 2013) Pfizer Comments General Comments:
FDA Draft Guidance for Industry Contract Manufacturing Arrangements for Drugs: Quality Agreements (May 2013) Pfizer Comments General Comments: 1. The terms owner and product owner are new and may result
More informationIMPLEMENTATION OF THE EU FALSIFIED MEDICINES DIRECTIVE, 2011/62/EU. IPA/EDQM/WHO 2012, Mumbai
IMPLEMENTATION OF THE EU FALSIFIED MEDICINES DIRECTIVE, 2011/62/EU from the perspective of Indian manufacturers and Indian authorities IPA/EDQM/WHO 2012, Mumbai S.M.MUDDA Micro Labs Limited, Bangalore
More informationCombination Products Part 4 Compliance and Implementation at multi-site Network
Combination Products Part 4 Compliance and Implementation at multi-site Network Vijay Damodaran Eli Lilly & Company September 27, 2017 Contents Key cgmp requirements for combination products How to perform
More informationLABORATORY COMPLIANCE
1 LABORATORY COMPLIANCE Jeanne Moldenhauer Vectech Pharmaceutical Consultants, Inc. Farmington Hills, MI INTRODUCTION Implementation of the Systems-Based Inspection Guideline for drug manufacturers in
More informationGMP The Other Side of Chemistry, Manufacturing & Controls (CMC)
Overview of USFDA Drug Regulatory Requirements Pharmaceutical Quality and Facility Inspections (GMP) Session II 19 February 2014 Casablanca, Morocco GMP The Other Side of Chemistry, Manufacturing & Controls
More informationKorea GMP & DMF. April Korea Pharmaceutical Traders Association Deputy director Oh Hyun, Kwon
Korea GMP & DMF April. 2015 Korea Pharmaceutical Traders Association Deputy director Oh Hyun, Kwon Contents 1. KPTA 2. Pharmaceutical industry 3. KGMP 4. KDMF KPTA KPTA Purpose ㅇ Trade promotion of pharmaceuticals,
More information